167 related articles for article (PubMed ID: 38442428)
1. Monitoring the Long-Term Effectiveness of Miltefosine in Indian Post-Kala-Azar Dermal Leishmaniasis.
Roy S; Moulik S; Roy M; Ghosh MK; Chaudhuri SJ; Pandey DK; Jain S; Dagne DA; Chatterjee M
Am J Trop Med Hyg; 2024 Apr; 110(4):656-662. PubMed ID: 38442428
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
[TBL] [Abstract][Full Text] [Related]
3. Antimony susceptible
Ghosh S; Verma A; Kumar D; Deep DK; Ramesh V; Salotra P; Singh R
Microbiol Spectr; 2024 Jun; 12(6):e0402623. PubMed ID: 38712926
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Recombinase Polymerase Amplification assay for monitoring parasite load in patients with kala-azar and post kala-azar dermal leishmaniasis.
Roy M; Ceruti A; Kobialka RM; Roy S; Sarkar D; Wahed AAE; Chatterjee M
PLoS Negl Trop Dis; 2023 Apr; 17(4):e0011231. PubMed ID: 37075066
[TBL] [Abstract][Full Text] [Related]
5. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
6. Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.
Sarraf NR; Mukhopadhyay S; Banerjee A; Das AK; Roy S; Chakrabarti S; Manna M; Saha P
Acta Trop; 2021 Nov; 223():106086. PubMed ID: 34389331
[TBL] [Abstract][Full Text] [Related]
7. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
8. Advanced case of PKDL due to delayed treatment: A rare case report.
Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cellular immunological responses in mono- and polymorphic clinical forms of post-kala-azar dermal leishmaniasis in India.
Kaushal H; Bras-Gonçalves R; Avishek K; Kumar Deep D; Petitdidier E; Lemesre JL; Papierok G; Kumar S; Ramesh V; Salotra P
Clin Exp Immunol; 2016 Jul; 185(1):50-60. PubMed ID: 26948150
[TBL] [Abstract][Full Text] [Related]
10. An In-depth Proteomic Map of Leishmania donovani Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient.
Routaray CB; Kumar A; Sundar S; Sathe G; Pawar H; Pai K
Acta Parasitol; 2022 Jun; 67(2):687-696. PubMed ID: 35020128
[TBL] [Abstract][Full Text] [Related]
11. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
[TBL] [Abstract][Full Text] [Related]
12. Liposomal amphotericin B is more effective in polymorphic lesions of post kala-azar dermal leishmaniasis.
Moulik S; Sengupta R; Ghosh MK; Das NK; Saha B; Chatterjee M
Indian J Dermatol Venereol Leprol; 2022; 88(2):201-206. PubMed ID: 33969651
[TBL] [Abstract][Full Text] [Related]
13. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.
Salam MA; Siddiqui MA; Nabi SG; Bhaskar KR; Mondal D
J Health Popul Nutr; 2013 Jun; 31(2):294-7. PubMed ID: 23930349
[TBL] [Abstract][Full Text] [Related]
14. Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies.
Mondal D; Bern C; Ghosh D; Rashid M; Molina R; Chowdhury R; Nath R; Ghosh P; Chapman LAC; Alim A; Bilbe G; Alvar J
Clin Infect Dis; 2019 Jul; 69(2):251-258. PubMed ID: 30357373
[TBL] [Abstract][Full Text] [Related]
15. Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
Hasnain G; Shomik MS; Ghosh P; Rashid MO; Hossain S; Hamano S; Mondal D
Am J Trop Med Hyg; 2016 Dec; 95(6):1383-1385. PubMed ID: 27672208
[TBL] [Abstract][Full Text] [Related]
16. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Ramesh V; Singh R; Avishek K; Verma A; Deep DK; Verma S; Salotra P
PLoS Negl Trop Dis; 2015; 9(10):e0004093. PubMed ID: 26492039
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of blood based quantitative PCR as a molecular diagnostic tool for post kala-azar dermal leishmaniasis (PKDL).
Kumar A; Singh VK; Madhukar P; Tiwari R; Roy R; Rajneesh ; Mehrotra S; Sundar S; Kumar R
Mol Biol Rep; 2024 Jun; 51(1):716. PubMed ID: 38824237
[TBL] [Abstract][Full Text] [Related]
18. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
19. Detection of asymptomatic Leishmania infection in Bangladesh by antibody and antigen diagnostic tools shows an association with post-kala-azar dermal leishmaniasis (PKDL) patients.
Owen SI; Hossain F; Ghosh P; Chowdhury R; Hossain MS; Jewell C; Cruz I; Picado A; Mondal D; Adams ER
Parasit Vectors; 2021 Feb; 14(1):111. PubMed ID: 33597000
[TBL] [Abstract][Full Text] [Related]
20. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
